Patents by Inventor Juswinder Singh

Juswinder Singh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MK2 INHIBITORS AND USES THEREOF
    Publication number: 20190135835
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: November 19, 2018
    Publication date: May 9, 2019
    Inventors: Matthew David Alexander, Joseph John McDonald, Yike Ni, Deqiang Niu, Russell C. Petter, Lixin Qiao, Juswinder Singh, Tao Wang, Zhendong Zhu
  • HETEROARYL COMPOUNDS AND USES THEREOF
    Publication number: 20190117650
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Application
    Filed: June 1, 2018
    Publication date: April 25, 2019
    Inventors: Juswinder Singh, Russell C. Petter, Richland Wayne Tester, Arthur F. Kluge, Hormoz Mazdiyasni, William Frederick Westlin, III, Deqiang Niu, Lixin Qiao
  • MK2 inhibitors and uses thereof
    Patent number: 10253040
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: April 9, 2019
    Assignee: Celgene CAR LLC
    Inventors: Matthew David Alexander, Claudio Chuaqui, John Malona, Joseph John McDonald, Yike Ni, Deqiang Niu, Russell C. Petter, Juswinder Singh, Chittari Pabba
  • Heteroaryl compounds and uses thereof
    Patent number: 10189794
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Grant
    Filed: June 28, 2017
    Date of Patent: January 29, 2019
    Assignees: Celgene CAR LLC, Sanofi
    Inventors: Laura Akullian D'Agostino, Robert Tjin Tham Sjin, Deqiang Niu, Joseph John McDonald, Zhendong Zhu, Haibo Liu, Hormoz Mazdiyasni, Russell C. Petter, Juswinder Singh, Matthieu Barrague, Alexandre Gross, Mark Munson
  • HETEROCYCLIC COMPOUNDS AND USES THEREOF
    Publication number: 20180353508
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Application
    Filed: January 12, 2018
    Publication date: December 13, 2018
    Inventors: Kwangho Lee, Deqiang Niu, Russell C. Petter, Matthew Frank Baevsky, Juswinder Singh
  • MK2 inhibitors and uses thereof
    Patent number: 10138256
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: January 14, 2014
    Date of Patent: November 27, 2018
    Assignee: Celgene CAR LLC
    Inventors: Matthew David Alexander, Joseph John McDonald, Yike Ni, Deqiang Niu, Russell C. Petter, Lixin Qiao, Juswinder Singh, Tao Wang, Zhendong Zhu
  • Heteroaryl compounds and uses thereof
    Patent number: 10081606
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Grant
    Filed: September 15, 2017
    Date of Patent: September 25, 2018
    Assignee: Celgene CAR LLC
    Inventors: Kwangho Lee, Deqiang Niu, Russell C. Petter, Juswinder Singh
  • Substituted pyrido[2,3-d]pyrimidines as inhibitors of protein kinases
    Patent number: 10065966
    Abstract: The present invention provides compounds of formula I-h: useful as inhibitors of protein kinases, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Grant
    Filed: May 25, 2017
    Date of Patent: September 4, 2018
    Assignees: Celgene CAR LLC, Sanofi
    Inventors: Laura Akullian D'Agostino, Robert Tjin Tham Sjin, Deqiang Niu, Joseph John McDonald, Zhendong Zhu, Haibo Liu, Hormoz Mazdiyasni, Russell C. Petter, Juswinder Singh, Matthieu Barrague, Alexandre Gross, Mark Munson, Darren Harvey, Andrew Scholte, Sachin Maniar
  • 2,4-disubstituted pyrimidines useful as kinase inhibitors
    Patent number: 10010548
    Abstract: The present invention provides 2,4-disubstituted pyrimidine compounds useful as kinase inhibitors, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: July 3, 2018
    Assignee: Celgene CAR LLC
    Inventors: Juswinder Singh, Russell C. Petter, Richland Wayne Tester, Arthur F. Kluge, Hormoz Mazdiyasni, William Frederick Westlin, III, Deqiang Niu, Lixin Qiao
  • Substituted 2,4-diaminopyrimidines as kinase inhibitors
    Patent number: 9987276
    Abstract: The present invention provides 2,4-diaminopyrimidines, and/or pharmaceutically acceptable compositions thereof, as kinase inhibitors.
    Type: Grant
    Filed: March 24, 2016
    Date of Patent: June 5, 2018
    Assignee: Celgene CAR LLC
    Inventors: Juswinder Singh, Russell C. Petter, Richland Wayne Tester, Arthur F. Kluge, Hormoz Mazdiyasni, William Frederick Westlin, III, Deqiang Niu, Lixin Qiao
  • ERK inhibitors and uses thereof
    Patent number: 9980964
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: February 2, 2017
    Date of Patent: May 29, 2018
    Assignee: CELGENE CAR LLC
    Inventors: Nadia Haq, Deqiang Niu, Russell C. Petter, Lixin Qiao, Juswinder Singh, Zhendong Zhu
  • HETEROARYL COMPOUNDS AND USES THEREOF
    Publication number: 20180072687
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Application
    Filed: September 15, 2017
    Publication date: March 15, 2018
    Inventors: Kwangho Lee, Deqiang Niu, Russell C. Petter, Juswinder Singh
  • HETEROARYL COMPOUNDS AND USES THEREOF
    Publication number: 20180022713
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Application
    Filed: June 28, 2017
    Publication date: January 25, 2018
    Inventors: Laura Akullian D'Agostino, Robert Tjin Tham Sjin, Deqiang Niu, Joseph John McDonald, Zhendong Zhu, Haibo Liu, Hormoz Mazdiyasni, Russell C. Petter, Juswinder Singh, Matthieu Barrague, Alexandre Gross, Mark Munson
  • Heterocyclic compounds and uses thereof
    Patent number: 9867824
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Grant
    Filed: June 24, 2016
    Date of Patent: January 16, 2018
    Assignee: Celgene CAR LLC
    Inventors: Kwangho Lee, Deqiang Niu, Russell C. Petter, Matthew Frank Baevsky, Juswinder Singh
  • ERK inhibitors and uses thereof
    Patent number: 9796700
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: November 28, 2016
    Date of Patent: October 24, 2017
    Assignee: Celgene CAR LLC
    Inventors: Nadia Haq, Deqiang Niu, Russell C. Petter, Lixin Qiao, Juswinder Singh, Zhendong Zhu
  • MK2 inhibitors and uses thereof
    Patent number: 9790235
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: October 17, 2017
    Assignee: Celgene CAR LLC
    Inventors: Matthew David Alexander, Claudio Chuaqui, John Malona, Joseph John McDonald, Yike Ni, Deqiang Niu, Russell C. Petter, Juswinder Singh, Chittari Pabba
  • HETEROARYL COMPOUNDS AND USES THEREOF
    Publication number: 20170267685
    Abstract: The present invention relates to compounds useful as inhibitors of protein kinases, containing a cysteine residue in the ATP binding site. The invention further provides for pharmaceutically acceptable compositions comprising therapeutically effective amounts of one or more of the protein kinase inhibitor compounds and methods of using said compositions in the treatment of cancers and carcinomas.
    Type: Application
    Filed: May 25, 2017
    Publication date: September 21, 2017
    Inventors: Laura Akullian D'Agostino, Robert Tjin Tham Sjin, Deqiang Niu, Joseph John McDonald, Zhendong Zhu, Haibo Liu, Hormoz Mazdiyasni, Russell C. Petter, Juswinder Singh, Matthieu Barrague, Alexandre Gross, Mark Munson, Darren Harvey, Andrew Scholte, Sachin Maniar
  • Heteroaryl compounds and uses thereof
    Patent number: 9765038
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: September 19, 2017
    Assignee: Celgene CAR LLC
    Inventors: Kwangho Lee, Deqiang Niu, Russell C. Petter, Juswinder Singh
  • Ligand-Directed Covalent Modification of Protein
    Publication number: 20170218353
    Abstract: The present invention relates to enzyme inhibitors. More specifically, the present invention relates to ligand-directed covalent modification of proteins; method of designing same; pharmaceutical formulation of same; and method of use.
    Type: Application
    Filed: February 2, 2017
    Publication date: August 3, 2017
    Inventors: Russell C. Petter, Charles F. Jewell, Kwangho Lee, Aravind Prasad Medikonda, Deqiang Niu, Lixin Qiao, Juswinder Singh, Zhendong Zhu
  • ERK INHIBITORS AND USES THEREOF
    Publication number: 20170210729
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: February 2, 2017
    Publication date: July 27, 2017
    Inventors: Nadia Haq, Deqiang Niu, Russell C. Petter, Lixin Qiao, Juswinder Singh, Zhendong Zhu